Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umibecestat (CNP520) in participants at risk for Alzheimer's Disease
NCT03131453Phase 3Terminated
- Sponsor
- Novartis
- Start
- Aug 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial of umibecestat in Alzheimer's disease (AD) (3 arms), sponsored by Novartis. Primary endpoints: Time to Event (Diagnosis of Mild Cognitive Impairment or Dementia, Due to Alzheimer's Disease (AD)) and Change in the Alzheimer's Prevention Initiative Composite Cognitive (APCC) Test Score. Started Aug 2017; status: terminated.
02
Drugs
umibecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03131453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03131453.